Mirum Pharmaceuticals MIRM 深 沪
交易中 11-07 10:41:53 美东时间
68.55
+0.830
+1.23%
华盛通- 最 高68.765
- 今 开67.08
- 成交量 6.95万股
- 最 低 66.79
- 昨 收 67.72
- 总市值 34.44亿
- 52周最高 78.5445
- 市盈率 静 --
- 换手率 0.14%
- 52周最低 36.8801
- 委 比 -50.38%
- 总股本 5023.76万
- 历史最高 78.5445
- 量 比 0.68
- 振 幅 2.92%
- 历史最低 6.513
- 每 手 1
- 风险率 11.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $81
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $80 to $81.
11-05 19:32
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
Mirum Pharmaceuticals’ Volixibat Study: A Potential Breakthrough for PBC Itching
Mirum Pharmaceuticals (($MIRM)) announced an update on their ongoing clinical s...
10-28 06:29
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
10-17 09:58
8 Analysts Assess Mirum Pharmaceuticals: What You Need To Know
Mirum Pharmaceuticals (NASDAQ:MIRM) has been analyzed by 8 analysts in the last...
10-17 04:00
Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $81
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $75 to $81.
10-17 02:00
美股大行评级 | 217美元！花旗上调阿里巴巴目标价；多家机构集体上调麦克森、美光科技等目标价
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4美元升至4.25美元；瑞穗：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至56美元
09-25 09:52
TD Cowen Initiates Coverage On Mirum Pharmaceuticals with Buy Rating, Announces Price Target of $95
TD Cowen analyst Joseph Thome initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy rating and announces Price Target of $95.
09-25 00:01
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
